FRMM — Forum Markets, Share News
0.000.00%
Last trade - 00:00- $74.02m
- $34.32m
- $6.55m
Brief: 180 Life Sciences Says Entered Into New Licensing Agreement With University Of Oxford
Brief: 180 Life Sciences Provides Follow-Up Information On Oxford University And The Company’S Successful Dupuytren’S Phase 2B Clinical Trial Results
180 Life Sciences jumps as hand deformity therapy meets study main goals
Brief: 180 Life Sciences Expands Patent Portfolio
Brief: 180 Life Sciences Says Entered Into Settlement And Mutual Release Agreement With Mintz
Brief: Celltrion Healthcare Says Co And 180 Life Sciences Enter Into Memorandum Of Understanding
Brief: 180 Life Sciences Files Prospectus Related To Proposed Resale Of 515,315 Shares Of Common Stock By Selling Stockholders
Brief: 180 Life Sciences Corp Files For Resale Of 5.44 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Brief: 180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
Brief: 180 Life Sciences Regains Nasdaq Compliance For Certain Listing Rules
Brief: 180 Life Sciences Corp Says Nasdaq Provided Written Notice To It That It Has Determined That Co Complies With Its Rules
Brief: 180 Life Sciences Expands Scientific Fibrosis Platform With Collagen Vi As A Driver And Disease Biomarker In Human Fibrosis Published In The Febs Journal
Brief: 180 Life Sciences Joins Russell Microcap Index
Brief: 180 Life Sciences Corp. Announces The Appointment Of Russell T. Ray And Teresa Deluca To Board Of Directors
Brief: 180 Life Sciences Says Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report On Form 10-Q
Brief: 180 Life Sciences Corp. Announces Collection Of All Patient Data For Phase 2B Dupuytren’S Disease Trial
Brief: 180 Life Sciences Corp - Receives Expected Notification From Nasdaq Related To Delayed Annual Report On Form 10-K
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM